CD36 deficient humans were reported to have insulin resistance. CD36 gene knock out, however, did not induce insulin resistance in mice. Rather, insulin sensitivity was increased in CD362/2 skeletal muscle. Furthermore, defective insulin signalling was shown to be associated with increased CD36 expression in macrophages. In addition, ox-LDL produced a dramatic reduction of Glyceraldehyde-3-phosphate deshydrogenase in smooth muscle cells resulting in a marked reduction of glucose usage. Together, these observations suggest that CD36 is inversely correlated with insulin sensitivity and plasma lipoproteins. In contrast, animals over expressing CD36 in muscle exhibited decreased plasma concentrations of triglycerides and increased plasma insulin and glucose concentrations and CD36 deficiency induced insulin resistance in the liver of these animals. Therefore, opinions concerning a direct or indirect role of CD36 in insulin resistance and the development of type II diabetes are diverging. In summary, the preponderance of evidence Sodium Nigericin suggests that CD36 is a central receptor for the detection, accumulation and metabolism of lipids and fatty acids in different cells and tissues. CD36 could then function as a molecular bridge between the development of dyslipidaemia and insulin resistance. If so, it may represent an interesting therapeutic target for the treatment of atherosclerosis, type II diabetes and obesity and their associated cardiovascular diseases. In MCE Chemical BMS-582949 (hydrochloride) support with that hypothesis, we show that small molecules with anti-CD36 activity can reduce postprandial hyperlipidaemia and protect against type II diabetes and atherosclerosis. Sprague-Dawley rats were fed a rodent maintenance global diet. Postprandial plasma TG concentrations were determined during 6 hours after an olive oil test. Briefly, the animals were fasted overnight for 16 hr and then forced fed with 1 mL of olive oil. Blood samples were collected every hour through the tail vein. To identify chemical compounds with anti-CD36 function, a CD36-expressing HEK-293 cell line was established for high throughput screening of large chemical libraries. One series of pharmacophore was identified and optimized for their capacity to inhibit binding, uptake and accumulation of ox-LDL by
